Prazosin
Minipress, Minizide, Prazosin (prazosin) is a small molecule pharmaceutical. Prazosin was first approved as Minizide on 1982-01-01. It is used to treat hypertension, prostatic hyperplasia, raynaud disease, and urinary retention in the USA. The pharmaceutical is active against alpha-1A adrenergic receptor, alpha-1B adrenergic receptor, and alpha-1D adrenergic receptor. In addition, it is known to target alpha-2B adrenergic receptor, alpha-2A adrenergic receptor, and alpha-2C adrenergic receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Minipress, Prazosin (discontinued: Minipress, Prazosin)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| prazosin | ANDA | 2023-09-15 |
| prazosin hcl | ANDA | 2025-01-22 |
| prazosin hydrochloride | ANDA | 2025-11-24 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C02: Antihypertensives
— C02C: Antiadrenergic agents, peripherally acting
— C02CA: Alpha-adrenoreceptor antagonists, peripherally acting
— C02CA01: Prazosin
— C02L: Antihypertensives and diuretics in combination
— C02LE: Alpha-adrenoreceptor antagonists and diuretics
— C02LE01: Prazosin and diuretics
HCPCS
No data
Clinical
Clinical Trials
125 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | 3 | 7 | 3 | 6 | 10 | 29 |
| Hypertension | D006973 | EFO_0000537 | I10 | 3 | 3 | 2 | 10 | 8 | 25 |
| Alcoholism | D000437 | EFO_0003829 | F10.1 | 6 | 9 | 1 | 1 | 4 | 19 |
| Traumatic stress disorders | D040921 | — | — | 1 | 3 | 1 | 4 | 7 | 16 |
| Prostatic hyperplasia | D011470 | EFO_0000284 | N40 | 1 | 1 | 1 | 2 | 4 | 9 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | 1 | 1 | 1 | 1 | 1 | 5 |
| Parasomnias | D020447 | — | G47.5 | — | 1 | — | 2 | 2 | 5 |
| Pheochromocytoma | D010673 | — | — | — | 1 | 1 | 1 | 1 | 4 |
| Dyssomnias | D020920 | — | — | — | 1 | — | 1 | 1 | 3 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | — | 2 | — | 2 |
Show 27 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sleep wake disorders | D012893 | — | G47 | — | — | 1 | — | 3 | 4 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | 1 | 1 | — | 1 | 3 |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | — | — | 1 | — | 1 | 2 |
| Coronary disease | D003327 | — | — | — | — | 1 | — | 1 | 2 |
| Heart failure | D006333 | EFO_0003144 | I50 | 1 | — | 1 | — | — | 2 |
| Scorpion stings | D065008 | — | — | — | — | 1 | — | 1 | 2 |
| Hypercholesterolemia | D006937 | — | — | — | — | 1 | — | — | 1 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | 1 | — | — | 1 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | 1 | — | — | 1 |
| Poisoning | D011041 | EFO_0008546 | T65.91 | — | — | 1 | — | — | 1 |
Show 6 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 4 | 4 | — | — | 1 | 9 |
| Cocaine-related disorders | D019970 | — | F14 | 3 | 2 | — | — | 1 | 6 |
| Alcohol drinking | D000428 | EFO_0004329 | — | 1 | 2 | — | — | 2 | 5 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | 2 | 1 | — | — | 1 | 4 |
| Combat disorders | D003130 | — | — | 1 | 2 | — | — | 2 | 4 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | — | 1 | — | — | 2 | 3 |
| Covid-19 | D000086382 | — | U07.1 | — | 1 | — | — | 1 | 2 |
| Wounds and injuries | D014947 | — | T14.8 | — | 1 | — | — | 1 | 2 |
| Brain injuries | D001930 | — | S06.9 | 1 | 1 | — | — | 1 | 2 |
| Psychomotor agitation | D011595 | — | — | — | 1 | — | — | 1 | 2 |
Show 23 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 3 | — | — | — | 1 | 4 |
| Mood disorders | D019964 | EFO_0004247 | F30-F39 | 1 | — | — | — | 1 | 2 |
| Anxiety | D001007 | EFO_0005230 | F41.1 | 2 | — | — | — | — | 2 |
| Pure autonomic failure | D054970 | — | — | 1 | — | — | — | — | 1 |
| Cigarette smoking | D000073865 | — | — | 1 | — | — | — | — | 1 |
| Erectile dysfunction | D007172 | EFO_0004234 | F52.21 | 1 | — | — | — | — | 1 |
| Amphetamine-related disorders | D019969 | EFO_0004701 | F15 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hip fractures | D006620 | EFO_0003964 | S72.00 | — | — | — | — | 2 | 2 |
| Bone fractures | D050723 | EFO_0003931 | T14.8 | — | — | — | — | 2 | 2 |
| Sleep initiation and maintenance disorders | D007319 | — | F51.01 | — | — | — | — | 2 | 2 |
| Hyperplasia | D006965 | EFO_0000536 | — | — | — | — | — | 2 | 2 |
| Urinary retention | D016055 | — | R33 | — | — | — | — | 2 | 2 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | — | — | — | 1 | 1 |
| Angina pectoris | D000787 | EFO_0003913 | I20 | — | — | — | — | 1 | 1 |
| Microvascular angina | D017566 | — | — | — | — | — | — | 1 | 1 |
| Pain | D010146 | EFO_0003843 | R52 | — | — | — | — | 1 | 1 |
| Chronic disease | D002908 | — | — | — | — | — | — | 1 | 1 |
Show 14 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Prazosin |
| INN | prazosin |
| Description | Prazosin is a member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively. It has a role as an antihypertensive agent, an alpha-adrenergic antagonist and an EC 3.4.21.26 (prolyl oligopeptidase) inhibitor. It is a member of piperazines, a member of quinazolines, a member of furans, a monocarboxylic acid amide and an aromatic ether. |
| Classification | Small molecule |
| Drug class | antihypertensives (prazosin type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COc1cc2nc(N3CCN(C(=O)c4ccco4)CC3)nc(N)c2cc1OC |
Identifiers
| PDB | — |
| CAS-ID | 19216-56-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2 |
| ChEBI ID | 8364 |
| PubChem CID | 4893 |
| DrugBank | DB00457 |
| UNII ID | XM03YJ541D (ChemIDplus, GSRS) |
Target
Agency Approved
ADRA1D
ADRA1D
Organism
Homo sapiens
Gene name
ADRA1D
Gene synonyms
ADRA1A
NCBI Gene ID
Protein name
alpha-1D adrenergic receptor
Protein synonyms
adrenergic, alpha -1D-, receptor, adrenergic, alpha-1A-, receptor, Alpha-1A adrenergic receptor, Alpha-1D adrenoceptor, Alpha-1D adrenoreceptor, Alpha-adrenergic receptor 1a
Uniprot ID
Mouse ortholog
Adra1d (11550)
alpha-1D adrenergic receptor (P97714)
Alternate
NQO2
NQO2
Organism
Homo sapiens
Gene name
NQO2
Gene synonyms
NMOR2
NCBI Gene ID
Protein name
ribosyldihydronicotinamide dehydrogenase [quinone]
Protein synonyms
N-ribosyldihydronicotinamide:quinone reductase 2, NAD(P)H dehydrogenase, quinone 2, NAD(P)H menadione oxidoreductase-1, dioxin-inducible-2, NAD(P)H quinone dehydrogenase 2, NRH dehydrogenase [quinone] 2, NRH:quinone oxidoreductase 2, QR2, Quinone reductase 2, ribosyldihydronicotinamide dehydrogenase
Uniprot ID
Mouse ortholog
Nqo2 (18105)
ribosyldihydronicotinamide dehydrogenase [quinone] (Q9JI75)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Prazosin
+
Polythiazide
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Prazosin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 10,159 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,858 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use